Lurbinectedin is a medication used for the treatment of metastatic small cell lung cancer. The recommended dosage of lurbinectedin is 3.2 mg/m2 administered as an intravenous infusion over 60 minutes every 21 days [3]. It is important to note that the dosage may be adjusted based on individual patient factors such as age, body surface area, and overall health status. According to Drug Patent Watch, the patent for lurbinectedin is set to expire in 2038 [1]. Medscape reports that lurbinectedin has been granted accelerated approval by the FDA based on tumor response rate and duration of response [2].

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://reference.medscape.com/drug/zepzelca-lurbinectedin-4000075
[3] https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213702s000lbl.pdf